Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 54.55
-1.20 (-2.15%)
At close: Feb 13, 2026
Keymed Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 872.19 | 428.12 | 354.1 | 100.06 | 110.27 | - | |
Revenue Growth (YoY) | 968.17% | 20.91% | 253.87% | -9.26% | - | - |
Cost of Revenue | 41.94 | 12.2 | 36.88 | 2.59 | 17.2 | - |
Gross Profit | 830.25 | 415.92 | 317.22 | 97.48 | 93.07 | - |
Selling, General & Admin | 412.47 | 298.83 | 177.01 | 133.91 | 92.45 | 21.55 |
Research & Development | 764.18 | 735.19 | 596.28 | 507.37 | 358.16 | 127.4 |
Other Operating Expenses | 19.96 | 7.99 | 1.36 | 0.68 | 2.96 | 0.03 |
Operating Expenses | 1,197 | 1,042 | 774.65 | 641.97 | 453.57 | 148.98 |
Operating Income | -366.97 | -626.09 | -457.43 | -544.49 | -360.5 | -148.98 |
Interest Expense | -17.06 | -18.46 | -17.26 | -8.4 | -11.13 | -14.31 |
Interest & Investment Income | 86.58 | 88.33 | 88.35 | 54.32 | 7.01 | 5.48 |
Earnings From Equity Investments | -4.12 | -5.26 | -4.75 | -9.71 | -0.72 | - |
Currency Exchange Gain (Loss) | 3.32 | 18.15 | 11.08 | 139.03 | -54.72 | 21.78 |
Other Non Operating Income (Expenses) | 46.75 | 34.62 | 23.82 | 65.66 | -13.78 | 13.48 |
EBT Excluding Unusual Items | -251.51 | -508.71 | -356.19 | -303.6 | -433.84 | -122.54 |
Gain (Loss) on Sale of Investments | -2.28 | 0.06 | - | - | - | 0.16 |
Other Unusual Items | - | - | - | - | -3,459 | -696.47 |
Pretax Income | -253.79 | -508.65 | -356.19 | -303.6 | -3,893 | -818.85 |
Income Tax Expense | 3.32 | 6.26 | 1.6 | - | - | - |
Earnings From Continuing Operations | -257.1 | -514.91 | -357.79 | -303.6 | -3,893 | -818.85 |
Minority Interest in Earnings | -0.24 | -0.33 | -1.57 | -4.52 | 5.32 | 0.27 |
Net Income | -257.34 | -515.24 | -359.36 | -308.12 | -3,887 | -818.58 |
Net Income to Common | -257.34 | -515.24 | -359.36 | -308.12 | -3,887 | -818.58 |
Shares Outstanding (Basic) | 263 | 262 | 261 | 261 | 161 | 67 |
Shares Outstanding (Diluted) | 263 | 262 | 261 | 261 | 161 | 67 |
Shares Change (YoY) | 0.70% | 0.22% | 0.09% | 62.34% | 139.72% | - |
EPS (Basic) | -0.98 | -1.97 | -1.37 | -1.18 | -24.17 | -12.20 |
EPS (Diluted) | -0.98 | -1.97 | -1.37 | -1.18 | -24.17 | -12.20 |
Free Cash Flow | -854.73 | -997.55 | -682.11 | -680.76 | -386.42 | -139.17 |
Free Cash Flow Per Share | -3.25 | -3.81 | -2.61 | -2.61 | -2.40 | -2.07 |
Gross Margin | 95.19% | 97.15% | 89.59% | 97.42% | 84.40% | - |
Operating Margin | -42.08% | -146.24% | -129.18% | -544.15% | -326.93% | - |
Profit Margin | -29.50% | -120.35% | -101.49% | -307.92% | -3525.30% | - |
Free Cash Flow Margin | -98.00% | -233.00% | -192.63% | -680.33% | -350.44% | - |
EBITDA | -289.23 | -551.07 | -405.8 | -522.22 | -347.7 | -135.09 |
EBITDA Margin | -33.16% | -128.72% | -114.60% | - | - | - |
D&A For EBITDA | 77.74 | 75.01 | 51.63 | 22.27 | 12.8 | 13.89 |
EBIT | -366.97 | -626.09 | -457.43 | -544.49 | -360.5 | -148.98 |
EBIT Margin | -42.07% | -146.24% | -129.18% | - | - | - |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.